ACRO Biomedical Co., Ltd.

World-First Collagen Ophthalmic Matrix by ACRO Biomedical Debuts at Asia Biotech Expo (L130)
 
Pioneering regenerative solution offers new hope for millions of corneal transplant patients
 
Taipei, Taiwan – ACRO Biomedical Co., Ltd. (TWSE: 6748) announced today that its groundbreaking ABCcolla® Collagen Ophthalmic Matrix has received regulatory approval from Taiwan’s Ministry of Health and Welfare (MOHW), with registration number: MOHW Medical Device No. 008155. This milestone marks a significant advancement in regenerative medicine and offers new hope to millions of patients awaiting corneal transplants worldwide.
 
ACRO Biomedical will unveil the ABCcolla® Collagen Ophthalmic Matrix at the BIO Asia–Taiwan 2025 International Conference & Exhibition, taking place July 23–27 in Taipei. Visitors are invited to learn more at Booth L130.
 
According to the World Health Organization (WHO), more than 20 million people worldwide suffer from blindness due to corneal injuries or infections, yet only about 100,000 corneal transplants are performed each year. This massive shortage underscores the need for alternatives. Global Market Insights, Inc. projects the global corneal transplant market to reach USD 500 million in 2024, and grow to USD 1 billion by 2033, with a compound annual growth rate (CAGR) of 7.59% from 2025 to 2033.
 
The ABCcolla® Collagen Ophthalmic Matrix is the world’s first and only product to utilize supercritical carbon dioxide decellularization technology, effectively removing all cells and impurities from animal-derived corneal tissue while preserving its natural collagen scaffold. This process enhances biocompatibility, biodegradability, and supports tissue regeneration. The product has been awarded 15 international patents and received the Silver Award at the 2023 National Pharmaceutical Technology R&D Awards. Currently, there are no comparable products available in the Taiwanese market.
 
Manufactured from porcine corneal tissue—which closely resembles human corneal structure—the decellularized matrix serves as a biocompatible alternative to donated human corneas, significantly reducing the risk of immune rejection. After years of rigorous clinical trials, the ABCcolla® Collagen Ophthalmic Matrix has proven effective for patients with corneal damage due to melting, trauma, or infection, making it suitable for various types of corneal reconstruction surgeries. The company is preparing for product commercialization to meet clinical demand and improve patient outcomes.
 
“Our vision is to address the global shortage of transplantable tissues and organs, ensuring that every patient in need of a corneal transplant can receive timely care,” said Dr. DJ Hsieh, Chairman and CEO of ACRO Biomedical. “This approval not only validates our innovation—it brings hope to patients around the world.”
 
With a rapidly aging global population, growing prevalence of corneal disease, and increasing awareness of vision health, demand for corneal transplants and related technologies is expected to rise. By advancing this breakthrough solution, ACRO Biomedical aims to reduce dependency on donor tissue and restore sight to more patients worldwide. The company remains committed to driving innovation and establishing itself as a global leader in regenerative medicine.


​
▲ACRO Biomedical Team Develops Collagen Ophthalmic Matrix, Approved by Taiwan FDA